{"name":"PharmaCyte Biotech","slug":"pharmacyte","ticker":"PMCB","exchange":"OTC","domain":"pharmacyte.com","description":"PharmaCyte Biotech is a biotechnology company focused on developing treatments for cancer and other diseases using its signature live-cell encapsulation technology. The company's lead product, Cell-in-a-Box, is being developed for the treatment of pancreatic cancer. PharmaCyte Biotech has a strong pipeline of products in various stages of development, with a focus on oncology and cell therapy.","hq":"Reno, NV","founded":0,"employees":"","ceo":"Kenneth L. Waggoner","sector":"Oncology / Cell Therapy Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$28M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":438416,"netIncome":30656050,"cash":55168353,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"PharmaCyte Biotech Announces FDA Clearance to Proceed with Clinical Trial for Pancreatic Cancer Treatment","summary":"PharmaCyte Biotech announced that the FDA has cleared the company to proceed with a clinical trial for its pancreatic cancer treatment, Cell-in-a-Box.","drugName":"Cell-in-a-Box","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"PharmaCyte Biotech Reports Third Quarter 2023 Financial Results","summary":"PharmaCyte Biotech reported its third quarter 2023 financial results, with a net loss of $1.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRnV0cGFhbzZFOGp0YzF4RGRTazJEQ0VYZWQtbHlEck9hY29vOTVPTURsNTI4bTBaa2x5cjBqaXc3NkxoNVp4d2x0TmFpT1NBLTROUkV4WFJmX0FzNUpRTWk4VnJjQ21haDNRMWVtN3lHWGtiYnhwT1hRb3JROExQazFkQzh2amJuZnJwN01wVlhHbDJYaGRTekQ5UzUwVmRmM0N3aUxYVm5TSlRhcW02aHhOeGg4djZi?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67 - Stock Titan","headline":"PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVWtyMURRVFl0eDl5OWpMcTljcmF6eHhqM2lua3g4R05tUlRVZGlmMHQ2N0xtdGNwenZLR2tWOW9rVHdaT2FGWGJhcnZHbVZHODV0UnpjX2N5NEFNTjVackhYMFhLRUs1WHhtbkp3MEFfWTMyTDlwamw2LUxtMTJQME9fMWd4V3NqWXgwRUhOSWlGejNpWmFPMkM1M1EyNlZvVVpJOEdHR3k4eVduak9mR0ZRcDdtMm9q?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB) - Stock Titan","headline":"Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQWdEMFhlWGtaWTZJTE9EWDU4eGY1NHppckRPbWpPaUVjeWtvVWEyMGZHUVliUEx1UFJ4dFlkVnE2V3NvT3VwdWE0RVVnaEtJZHA2Z0tiMmZqU1B0Y2ptSXYyU3F3QTVNaklSbFo4THVISHBxY2JYUV81YTlmLVE4UXU5UktiN0FUX0wxc2MyQlBtaDFYdmpUSlBuTm5Dbl9rS3JpWWRvM1hnR24tNjFrZEQ3WW5OLU1L?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"Director at PharmaCyte Biotech (PMCB) gets 119,170 options - Stock Titan","headline":"Director at PharmaCyte Biotech (PMCB) gets 119,170 options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNNWlVV2sybmN3TTNmLXozU2ZoUGZRS1E5Wl9UWjRLZUdrRnUwb1FRaXhxcVBHWGpCQVVOMlAyWXlxSmVTRDJhVmZZNUtBaEpiLVhxM3ZYSExsMU0wMDlQMWRBc2x3TGFFOHRZLWdWX0Jsa2xWWHpraGVvRzlJNFhHTGVnazRMTnpKOUJ2Yk5zOU93OE1ERk9LN3o0NklFUHA3YjNNUGRHZW9yc1YwTWQtbmxB?oc=5","date":"2026-04-02","type":"regulatory","source":"Stock Titan","summary":"PharmaCyte Biotech (PMCB) wins approval for reverse split range and 2M new plan shares - Stock Titan","headline":"PharmaCyte Biotech (PMCB) wins approval for reverse split range and 2M new plan shares","sentiment":"positive"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q FOR JAN 2026","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxOV2hmbWI0V0dqMEZHdmhGakFnMWNmYXlRVVIwNmYzVFAxQk1xdlRHTkdaVVVMbU9wNWRLdjJlNkE5YUliMUVjWE12X0NKRE9RV0dUNl9OOExjdEhmY3NrYktHN1ZyV25DRWNobWd5RkhrTW9KeTNWSUZRcHZEdjNHRldNLXFEU21ZaHY4R0VhOFZ2d2gwZUd4ZFpwcEVrNEhDTE0wa2hVdF9KMnZ3Nmt1WkhMdi1POXVYS2F2YnNXQjlILW1mc0F0M2VwMGgxOV9KZUM4T3J1UmVaaHpNU3lseXF1Yk9aQXB2NjhOaGFQMjJnaWxKRlNDUHFBYVJ3cXVHSE5rcTZJV1gwR19WVUt6S2VlMkVSc2VOVVNlZkN6VURBRWN3ZlJSSE8zMXRWNjF0T3VvTlVQQU4yRDZUYVk3U2Q2R3AzZEdJbVd4RlQ5STA?oc=5","date":"2026-01-09","type":"pipeline","source":"Insider Monkey","summary":"Hedge Fund and Insider Trading News: Paul Singer, Steve Cohen, Israel Englander, Ray Dalio, Rokos Capital Management, Viking Global, PharmaCyte Biotech Inc (PMCB), Cloudflare Inc (NET), and More - Ins","headline":"Hedge Fund and Insider Trading News: Paul Singer, Steve Cohen, Israel Englander, Ray Dalio, Rokos Capital Management, Vi","sentiment":"neutral"},{"date":"2025-12-18","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q FOR OCT 2025","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPMzdoOHF6ejlacjFUZkJ2YWhFbDRrTzFwaFV4SVpvaFI2NXJDNXJqMzVza0J3dTlOYXItNjJ1OGFLczgxZGZVbEZiZFFid1p3bnVCTWkwazlKbjFXeGZGUEluYVQ0cEpRdjREMFZBR19aeGJqbWNMMEFyQTZWcDVUTg?oc=5","date":"2025-12-04","type":"pipeline","source":"StocksToTrade","summary":"PharmaCyte Biotech: Is Growth Here to Stay? - StocksToTrade","headline":"PharmaCyte Biotech: Is Growth Here to Stay?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPX1lMUVoweEpZaVA5aUY4UDZpeEZRemFSc21kYVE2eVpBRHFNd1pmVFNWQzRIdU1qQ2s0ZzYxTnNQWEtvVEI3YUhlRDU4NGpvVjNFWWdpS19xcFBGbldSUFl4eU5sS1JoTDVtN1o2UTZvaWhaN1BQZWRCcDctbXpFaXU5QjBFRlpPcHpYRFZDTTZ5bk82MHB0WHlsMDM4aXRwQ2sxQ1lKcEFKeVdzcG12Z3paVWoyVGVPSDhlTkpUVDhsbXdXUnhsWlNEa3NocURqdmVGMVhTVmg3bGpncDVOeFZNeGx5Nm8wY3N0Qg?oc=5","date":"2025-11-25","type":"regulatory","source":"investingnews.com","summary":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - investingnews.com","headline":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNSHlwY1BPbDhxcFFibl9jRmJtek9rVGtqS09LcERzN0NuMUx4SExxbzdHeWlLSUlSWllueVpXby0xdjRDWU5aMkFhS1hxc1lCWE9wVnhkcjNYVzdWTk9QY05OX1RWWFdKOUxFYW52QkpBU1FONE5OdzRBTzFSUFByZVVoVUlJbjk1WGZZazhxaEZQSlI4ZXNqSDZUb0Z0RFJXUEZQbHU5Z21uOTgzbGc?oc=5","date":"2025-09-12","type":"pipeline","source":"investingnews.com","summary":"PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors - investingnews.com","headline":"PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxPWW00REN3c2QxTWpIeGkyTXd1cEthaVIzYThfeUdPQjhLZHkzVGFqQnNBS1lUT0I3TEpSeXNqcGFHMVJhM2twbTB1M0k2bHozMFhHRU9aRHlHMmF6Y2duRTdvTklkbkJSUTFSdDVGSmFNVTNoVlgzc1hPXzdpZnNGZ1ZSTDB4eXYyWmdTdXVDTDZjSE5RZW05cFlVWWFjalhDREVMR3lMcUFyczdaLWdmNmtucmthS21pQ1hlNzIxR2F6c1dLWEVqcThkMVROd0Z1ZjFqdmtxbjZrX1E4YTF6aXhWOXdETllwTGpqakQzZ0ZPQjNOMlpXUjYtRFo2OFl0S3Vfd0tKRTFmekItdDg4V0tJX0hLMVZrRm9ZU3JrZ0plenM?oc=5","date":"2025-09-02","type":"deal","source":"investingnews.com","summary":"PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications - investingnews.com","headline":"PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Compu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPTlhPdjRLUi1HOFNVVXpjQi1keE05dlNrR191R1JuM0xNcTMwVTFDZHo2ZloyZTBaY2Q4cGlUemQwOGRkX3hHdlNic2VLVEdlZVdhMXpWN0pQSnRjdnR5dzZmRnlHRWtDeE1BaVRiTE9reExJVHZGNUR0MkhKVHYzZnIwR1lrdnNRVm90Y1RDb3d3OGdBSldYWGlkVzEzMVZ5Q2lWYzQ3WXVFX3BBMGs4Y2JqZDFyZw?oc=5","date":"2023-06-15","type":"pipeline","source":"Business Wire","summary":"PharmaCyte Biotech Announces Final Results of Tender Offer - Business Wire","headline":"PharmaCyte Biotech Announces Final Results of Tender Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1kR0tzbEZqR19pVEM3Q0tYWFUtV2FONmxlclhZVnNHUnpEZEVEMVA0Q3dxVlJ5a1dpNVU2Tm9UanJLMmh4N3NlelVUMjQ2N2xNOS1sNVg3ZU9jMXhR?oc=5","date":"2021-08-11","type":"pipeline","source":"TradingView","summary":"PMCB Stock Price and Chart — NASDAQ:PMCB - TradingView","headline":"PMCB Stock Price and Chart — NASDAQ:PMCB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBVYnBGUkJ2SElfU1VGOEFLTk11ZjhfUGVKc19UdTVnVjF1V2pCZU13elkwcnNfVXprcDJWMkVkelRvSEhjZkREM1NjYzhfaWRQWlE?oc=5","date":"2017-05-20","type":"pipeline","source":"Yahoo! Finance Canada","summary":"PharmaCyte Biotech, Inc. (PMCB) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"PharmaCyte Biotech, Inc. (PMCB) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Celgene","Bristol-Myers Squibb","Merck & Co."],"therapeuticFocus":["Oncology","Cell Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-04-30","revenueHistory":[{"value":0,"period":"2025-04-30"},{"value":0,"period":"2024-04-30"},{"value":0,"period":"2024-04-30"},{"value":0,"period":"2023-04-30"},{"value":0,"period":"2023-04-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":438416,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":30656050,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":55168353,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}